Frequency Therapeutics has appointed William Chin to serve as the Woburn, MA, company’s chief medical officer. Chin’s previous experience includes posts at Eli Lilly (NYSE: [[ticker:LLY]]), where he was senior vice president, drug discovery and clinical investigation, and the Pharmaceutical Research and Manufacturers of America, where he was executive vice president of scientific and regulatory affairs. Frequency, an MIT spinout that raised $32 million in a Series A round of financing last year, is developing drugs that treat hearing loss.